(HealthDay)—Imbruvica (ibrutinib) has been approved by the U.S. Food and Drug Administration to treat mantle cell lymphoma (MCL), a rare but aggressive form of blood cancer.
Nov 13, 2013
0
0
(HealthDay)—The U.S. Food and Drug Administration on Wednesday expanded approval for the anti-cancer drug Imbruvica (ibrutinib) to include adults with chronic graft versus host disease (cGVHD).
Aug 2, 2017
0
1
Researchers in Spain have determined how a transcription factor known as Mirror regulates tumour-like growth in the intestines of fruit flies. The scientists believe a related system may be at work in humans during the progression ...
Oct 8, 2014
0
0
Israeli scientists are moving closer to understanding how multiple myeloma takes hold in bone marrow by identifying what they believe are the mechanisms used by cancer cells to take over. In particular, they have found that ...
Oct 3, 2016
0
1
Joseph Pidala, M.D., M.S., assistant member of the Blood and Bone Marrow Transplant and Immunology programs at Moffitt Cancer Center, and colleagues from the Chronic Graft-Versus-Host Disease Consortium have determined that ...
Jun 17, 2013
0
0
Researchers in the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute discovered in pre-clinical models that dormant prostate cancer cells found in bone tissue can be reawakened, causing metastasis to other parts of ...
Jan 29, 2014
0
0
Anti-androgen hormonal therapy, also called chemical castration, can be an important defense against further disease progression for patients with prostate cancer that has traveled and grown in other areas, or metastasized—but ...
Jun 9, 2014
0
3
Early treatment response is a powerful predictor of long-term outcome for young patients with acute myeloid leukemia (AML). The information can help physicians decide whether a more intensive approach is needed. Research ...
Sep 10, 2012
0
0
Multiple myeloma (MM) is the second most common type of blood cancer. It attacks the plasma cells in the blood. A team at the Technical University of Munich (TUM) has now discovered a mechanism which provides indications ...
Dec 12, 2022
0
9
Nine of twelve leukemia patients who received infusions of their own T cells after the cells had been genetically engineered to attack the patients' tumors responded to the therapy, which was pioneered by scientists in the ...
Dec 10, 2012
0
0
